Hypera Sa Stock Price, News & Analysis
Company Description
Hypera Sa (OTC Link: HYPMY) is a publicly traded drug manufacturers - specialty & generic company in the Healthcare sector. The company has a market capitalization of $2.7B.
HYPMY stock has gained 6.8% over the past year. Shares last traded at $4.43.
This page provides a comprehensive overview of HYPMY stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Hypera Sa (HYPMY) stock last traded at $4.43, down 3.49% from the previous close. Over the past 12 months, the stock has gained 6.8%. At a market capitalization of $2.7B, HYPMY is classified as a mid-cap stock with approximately 703.5M shares outstanding.
Latest News
Hypera Sa has 3 recent news articles. Of the recent coverage, 0 articles coincided with positive price movement and 3 with negative movement. Key topics include earnings, acquisition. View all HYPMY news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Hypera Sa (HYPMY) currently stands at 3.0 thousand shares, up 18800.0% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has increased by 18800%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Hypera Sa (HYPMY) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 1.9 days.
HYPMY Company Profile & Sector Positioning
Hypera Sa (HYPMY) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing HYPMY often look at related companies in the same sector, including Almirall (LBTSF), Almirall SA (ALMRY), Procaps Group Sa (PROCF), Sumitomo Dainippon Pharma (SMDPY), and Hikma Pharmaceuticals Plc (HKMPY). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate HYPMY's relative position within its industry.